ArticleScientific reports2025
Integrated bulk and single cell sequencing with experimental validation identifies type 2 diabetes biomarkers.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Type 2 diabetes (T2D) is a group of metabolic disorders characterized by chronic hyperglycemia and long-term carbohydrate, fat, and protein metabolism disruptions. This study aimed to identify biomarker of T2D and analyze immune cell infiltration in the islets of T2D patients. Using the GSE76895 dataset, 112 differentially expressed genes (DEGs) were identified between islet samples from T2D and non-diabetic (ND) individuals. Then, 112 DEGs were used for functional enrichment and Gene Set Enrichment Analyses (GSEA). Through the least absolute shrinkage and selection operator (LASSO) and support vector machine-recursive feature elimination (SVM-RFE), SLC2A2 emerged as the most likely candidate biomarker of T2D. Moreover, the distribution of tissue-infiltrating immune cells between T2D and ND islet samples was assessed using the CIBERSORT algorithm. The result revealed that resting CD4
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.